Register for free to listen to this article

Thank you. Listen to this article using the player above. ✖


Want to listen to this article for FREE?


Complete the form below to unlock access to ALL audio articles.

A research team at Kumamoto University has identified a genetic mechanism that enables the human T-cell leukemia virus type 1 (HTLV-1) to remain dormant and undetectable in the body. The findings, published in Nature Microbiology on May 13, 2025, highlight a viral silencer sequence that suppresses HTLV-1 gene expression and may offer insights for future therapies targeting retroviral infections.

HTLV-1 (Human T-cell leukemia virus type 1)
A retrovirus that infects T-cells and is associated with adult T-cell leukemia/lymphoma (ATL) and inflammatory disorders. It is endemic in some regions of Japan, the Caribbean, and parts of Africa.

HTLV-1 is a retrovirus that can cause adult T-cell leukemia/lymphoma (ATL), an aggressive cancer. While many infected individuals never show symptoms, some eventually develop leukemia or inflammatory diseases. The virus is able to persist in the body by entering a latent state, where its genes are largely inactive, reducing its visibility to the immune system.

Identifying a silencing mechanism within the virus

In this study, the researchers mapped the HTLV-1 genome and discovered a region that acts as a transcriptional silencer. This element was found to recruit the host’s own RUNX1 transcription factor complex, which blocks the expression of viral genes. In laboratory models, removal or mutation of this silencer sequence led to greater viral activity and increased immune system recognition.

RUNX1 transcription factorA protein complex involved in gene regulation that plays a role in blood cell development and cancer. 

The study was led by Professor Yorifumi Satou of the Joint Research Center for Human Retrovirus at Kumamoto University. His team’s findings reveal a viral strategy for maintaining dormancy that is built into the genetic architecture of HTLV-1 itself.

Application to HIV latency and treatment

To test whether the silencer could affect other retroviruses, the researchers inserted the sequence into HIV-1, the virus that causes AIDS. When modified in this way, the HIV virus showed reduced replication and lower levels of host cell killing, suggesting a shift toward latency.

This finding indicates that the silencer mechanism discovered in HTLV-1 may be repurposed to develop new strategies for managing HIV and potentially other retroviruses. By promoting a controlled latent state, it may be possible to reduce the harmful effects of viral replication while enhancing the ability of therapies to target infected cells.

Implications for treatment in endemic regions

HTLV-1 infection is concentrated in certain areas, including parts of southwestern Japan, the Caribbean and Central Africa. The identification of a viral latency mechanism offers a clearer understanding of how the virus persists for decades and may help inform strategies to limit progression to leukemia or other conditions.

Reference: Sugata K, Rahman A, Niimura K, et al. Intragenic viral silencer element regulates HTLV-1 latency via RUNX complex recruitment. Nat Microbiol. 2025;10(6):1447-1462. doi: 10.1038/s41564-025-02006-7

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

This content includes text that has been generated with the assistance of AI. Technology Networks’ AI policy can be found here.